You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兩大藥廠大戰!葛蘭素史克美國起訴輝瑞侵犯RSV疫苗專利
阿思達克 08-03 01:20
英國生物製藥龍頭葛蘭素史克(GSK.US)周三在美國法院起訴輝瑞(PFE.US),指控輝瑞旗下呼吸道合胞病毒(RSV)疫苗Abrysvo侵犯葛蘭素史克其RSV疫苗Arexvy中的專利權。 葛蘭素史克表示,輝瑞的疫苗侵犯其四項專利,均與其疫苗用於對抗呼吸道疾病的抗原有關。葛蘭素史克發言人稱,保護知識產權保護是研究型公司推動創新能力的基礎,預期訴訟不會影響葛蘭素史克推出Arexvy的能力。 輝瑞於一份聲明中表示,對其知識產權地位充滿信心,並將堅決捍衛將Abrysvo帶予患者的權利。 兩大藥廠的RSV疫苗均於今年5月獲得美國食品和藥物管理局批准用於60歲以上成年人身上,為首批獲批用於預防RSV的疫苗。據政府預期,RSV每年導致美國約1.4萬名65歲及以上成年人死亡。 有分析稱,輝瑞和葛蘭素史克正爭奪RSV疫苗市場,RSV疫苗市場於2030年或超過100億美元,目前RSV疫苗為兩間公司舊有藥物戰略的一部分,舊有藥物正面臨更便宜的仿製藥競爭。 葛蘭素史克跌0.6%;輝瑞升0.2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account